Trial Profile
Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function in dyslipidemic patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III/IV
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Pravastatin (Primary)
- Indications Dyslipidaemias
- Focus Pharmacodynamics
- 24 May 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2013 New trial record